Search
NDX-3315
go.drugbank.com/drugs/DB18671InvestigationalNDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled [heparin].
Palazestrant
go.drugbank.com/drugs/DB18971InvestigationalStandard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).
Nelonicline
go.drugbank.com/drugs/DB19040InvestigationalNelonicline is under investigation in clinical trial NCT01678755 (A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia).
Atilotrelvir
go.drugbank.com/drugs/DB19439InvestigationalAtilotrelvir is under investigation in clinical trial NCT05041907 (Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)).
Utatrectinib
go.drugbank.com/drugs/DB21295InvestigationalUtatrectinib is under investigation in clinical trial NCT01468324 (AZD7451 for Recurrent Gliomas). Utatrectinib has a monoisotopic molecular weight of 382.17 Da. … Utatrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Utatrectinib is a tropomyosin receptor kinase (TRK) inhibitor.
Rupintrivir
go.drugbank.com/drugs/DB05102ExperimentalRupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections. … Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus.
Clevudine
go.drugbank.com/drugs/DB06683InvestigationalSynonyms: L-FMAU, 2'-Fluoro-5-methyl-beta-L-arabinofuranosyluracilCategories: Antivirals for Systemic Use, Antiinfectives for Systemic UseMDX-214
go.drugbank.com/drugs/DB06110ExperimentalIt is developed for the treatment of EGF-R overexpressing cancers. … MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector
XTL-6865
go.drugbank.com/drugs/DB06058InvestigationalIt is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.
Ferumoxides
go.drugbank.com/drugs/DB09508ApprovedCategories: Compounds used in a research, industrial, or household setting